Insanity: Four Decades of U.S. Counterdrug Strategy

Abstract

In the four decades since President Nixon first declared war on drugs the U.S. counterdrug strategy has remained virtually unchanged favoring supply-reduction, law enforcement and criminal sanctions over demand-reduction, treatment and education. While the annual counterdrug budget has ballooned from $100 million to $25 billion, drug availability of most illicit drugs remains at an all-time high. The human cost is staggering nearly 40,000 drug-related deaths in the U.S. annually. The societal impact, in purely economic terms, is now estimated to be approximately $200 billion per year. And the global illicit drug industry now accounts for 1 percent of all commerce on the planet approximately $320 billion annually. Legalization is almost certainly not the answer; however, an objective analysis of available data confirms that: 1) the U.S. has pursued essentially the same flawed supply-reduction strategy for forty years; and 2) simply increasing the amount of money invested each year in this strategy will not make it successful. Faced with impending budget cuts and a future of budget austerity, policymakers must replace the longstanding U.S. counterdrug strategy with a pragmatic, science-based, demand-reduction strategy that offers some prospect of reducing the economic and societal impacts of illicit drugs on American society.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Apr 01, 2012
Accession Number
ADA568835

Entities

People

  • Michael F. Walther

Organizations

  • United States Army War College

Tags

Communities of Interest

  • Biomedical

DTIC Thesaurus Topics

  • Civil Rights
  • Commerce
  • Congress
  • Criminal Justice System
  • Criminals
  • Drug Abuse
  • Drug Addiction
  • Drug Trafficking
  • Health Services
  • Human Population
  • Law
  • Medical Personnel
  • National Politics
  • Public Policy
  • Societies
  • Street Drugs
  • War Colleges

Readers

  • Child and Adolescent Substance Abuse Science in Autism Spectrum Disorders.
  • Economics